logo-loader
viewProvention Bio Inc

Provention Bio soars as single course of PRV-031 delays onset of Type 1 diabetes in high-risk patients

The drug, also known as teplizumab, is being developed for the interception and prevention of Type 1 diabetes

Tiles spelling out diabetes
The clinical-stage biopharma is developing PRV-031 for the interception and prevention of Type 1 diabetes

Provention Bio Inc (NASDAQ:PRVB) soared Monday, a day after revealing that a single course of the company’s drug PRV-031 (teplizumab) delays the onset of Type 1 diabetes in high-risk individuals by at least two years.

The Oldwick, New Jersey, company presented encouraging data from its At-Risk study at the American Diabetes Association annual meeting.

Shares in Provention Bio more than doubled, to $11.28 per share, in pre-market trade.

READ: Provention Bio rises after saying Phase 3 study for diabetes drug candidate to begin in 2Q

The study enrolled 76 participants aged 8 to 49 who were at risk because they had two or more T1D autoantibodies and “abnormal glucose metabolism,” said the company. At least 72% of the participants were under 18. The subjects were randomized to receive either PRV-031 or a placebo.

Results from the study showed that a single 14-day course of PRV-031 "significantly delayed" the onset and diagnosis of clinical T1D, as compared to placebo, by a median of 2 years in children and adults considered to be at high risk, reported the company.

The median time to clinical diagnosis of T1D for placebo participants was just over 24 months. In comparison, the median time for PRV-031 treated participants to clinical diagnosis of T1D was just over 48 months.

"This groundbreaking study demonstrates that we can use immunotherapy, specifically PRV-031, to prevent or significantly delay the onset of clinical Type 1 diabetes by at least two years in individuals who will almost certainly progress to clinical disease," said Dr Eleanor Ramos, chief medical officer at Provention Bio.

Ramos said approximately 60% of subjects in the study did not develop T1D following only one course of PRV-031 therapy, “double the placebo group.”

“Teplizumab is the first immune modulator to show a delay in the clinical onset of type 1 diabetes," said Ramos.

Meanwhile, Dr Kevan Herold, Professor of Immunobiology and Medicine at Yale University, who is the lead author of the study, said the results have “real clinical meaning” for individuals at-risk of developing clinical type 1 diabetes such as “family members of patients.”

“Delaying the onset of clinical T1D may mean the disease burden could be postponed to a point at which patients are better able to manage their disease such as after infancy, elementary school, high school or even college,” pointed out Herold.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive

Quick facts: Provention Bio Inc

Price: 9.08 USD

NASDAQ:PRVB
Market: NASDAQ
Market Cap: $435.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Southern Gold active on the ground in South Korea with multiple rigs and...

Southern Gold Limited's (ASX:SAU) managing director Simon Mitchell tells Proactive London's Andrew Scott they're looking to become recognised as the go-to name for exploration in South Korea.  ''We're now 100% focused on South Korea and I think that's been well received by the market to...

1 hour, 43 minutes ago

2 min read